P21 for Health & Longevity
Evidence Review created on 10/27/2026 using AI4L + evidence-mcp / Opus 5.5
Also known as: P021, Peptide 021, Peptide 21, Ac-DGGLAG-NH2
Motivation
P21, also written P021, is a short laboratory-made peptide built from five amino acids and modelled on a small active piece of a natural nerve-cell growth signal. It was designed so that the fragment could reach the brain, which the whole signal cannot do. Interest in it centres on three things: the birth of new nerve cells, the strength of the connections between them, and the proteins that accumulate in aging brains.
The natural signal P21 was cut from was given to people in the 1990s for a motor-nerve disease, and a modified version later for weight loss, which is where human experience with this family of molecules comes from. P21 itself has been studied only in cells and animals, by few laboratories. It is nonetheless sold through unregulated channels and used without a prescription.
This review examines what the published record shows and does not show about P21: how it is thought to work, what has been measured and in what, what the absence of human data means for the claims made about it, and what is known about its risks, sourcing and the interests behind the research.
Benefits - Risks - Protocol - Conclusion
Recommended Reading
A short, curated list of sources that give a high-level overview of P21, its mechanism, and the state of the evidence behind it.
-
Effects of a ciliary neurotrophic factor (CNTF) small-molecule peptide mimetic in an in vitro and in vivo model of CDKL5 deficiency disorder - Mottolese et al., 2024
The one Bologna-led live-animal test of P21’s signature effect, co-authored by its patent-holding inventor: in mice lacking Cdkl5 (a gene needed for brain development), it raised no brain-derived neurotrophic factor (BDNF, a nerve-cell growth signal).
-
The development of peptide- and oligonucleotide-based drugs to prevent the formation of abnormal tau in tauopathies - Lozupone et al., 2023
An independent review that places P21 beside gene-silencing drugs aimed at tau (a brain protein that clumps together in dementia), giving the compound’s standing without the inventing laboratory’s framing.
-
Neurotrophic Factors in Stroke, Traumatic Brain Injury, and Neurodegeneration: A Convergent Pathophysiological and Translational Perspective - Shcheblykina et al., 2026
A category review of nerve-growth signals and the small molecules that imitate them — the ciliary neurotrophic factor pathway P21 was cut from — and of why brain delivery has blocked clinical translation.
-
P21 (P021) - Nick Urban
A consumer-facing assessment that states plainly there are no human trials of P21; the site rates compounds commercially and carries affiliate offers, so its framing carries a selling interest.
-
The Brain Peptide You Don’t Know About - Hunter Williams
A practitioner newsletter describing how P21 is sourced and dosed in grey-market practice; it carries a discount code for a peptide vendor. A record of actual use, not evidence that it works.
Note on priority sources and interests: No relevant content on P21 was found on foundmyfitness.com, peterattiamd.com, hubermanlab.com, chriskresser.com, lifeextension.com or lifespan.io. Each site’s own search and a separate web search for the expert’s name plus the compound returned nothing on it, so no priority-platform item is listed. Almost all efficacy work on P21 comes from a single laboratory — that of Khalid Iqbal at the New York State Institute for Basic Research in Developmental Disabilities — which holds the governing patents through the Research Foundation for Mental Hygiene (US patent 9,327,011) and, according to author affiliations on Mottolese 2024, is tied to a commercial developer, Phanes Biotech. Every animal study of P21 cited below lists Iqbal as an author, including the one Bologna-led study (Mottolese 2024). The two consumer sources listed sell or promote content and products in this market, which is noted in their annotations. No institutional payer has a stake on either side: P21 is not reimbursed anywhere and displaces no reimbursed therapy, so the payer-driven cost asymmetry that can shape guideline formation for approved drugs does not operate here.
Grokipedia
No Grokipedia article exists for P21. The site’s “p21” article covers cyclin-dependent kinase inhibitor 1A (CDKN1A, the gene for a protein that halts cell division), an unrelated molecule that happens to share the label.
Examine
No Examine article exists for P21. The compound is not a dietary ingredient and is not sold as a supplement, which places it outside the site’s coverage.
ConsumerLab
No ConsumerLab article exists for P21. The site tests consumer supplements and foods; P21 is sold only as a research chemical, so no product in its testing scope contains it.
Systematic Reviews
No systematic reviews or meta-analyses for P21 were found on PubMed as of October 27, 2026.
Neither side of the trade-off is represented in this literature: there is no systematic review or meta-analysis of P21’s claimed cognitive and neuroprotective effects, and none of its principal risk, which is unknown human safety.
Mechanism of Action
P21 is a five-residue peptide, Ac-DGGLAG-NH2, copied from residues 148–151 of ciliary neurotrophic factor (CNTF, a natural survival signal for nerve cells) with an adamantylated glycine added at one end to raise brain entry and block digestion by peptide-cutting enzymes (Baazaoui 2017). Two mechanisms are proposed by the inventing laboratory, which holds the patents on the compound. First, it competitively blocks signalling by leukemia inhibitory factor (LIF, a related messenger that restrains the formation of new nerve cells), releasing a brake on neurogenesis (the birth of new neurons) (Kazim 2016, a review). Second, it raises BDNF, which acts through the TrkB-PI3K-AKT pathway (a receptor-driven survival cascade) to place an inhibitory phosphate on glycogen synthase kinase-3β (GSK-3β, the main enzyme that over-phosphorylates tau), lowering tau and amyloid-β (the plaque-forming protein) pathology (Kazim 2014).
A competing mechanistic reading exists. A Bologna-led group, with Iqbal as co-author, found P21 corrected cell-level deficits in human nerve cells lacking CDKL5, yet in live Cdkl5-null mice it raised no BDNF in the hippocampus (the brain’s memory centre) and changed no brain structure (Mottolese 2024).
Pharmacological properties: molecular weight 578.3; plasma half-life over three hours (a review, Kazim 2016); blood-brain barrier permeable; orally active in rodents; stable above 95% in artificial gastric juice for 30 minutes (earlier data restated in Baazaoui 2017). No human half-life, receptor-binding selectivity, quantitative tissue distribution, or metabolising enzymes have been published; peptidase cleavage rather than cytochrome P450 (CYP, the liver’s main drug-processing enzyme family) oxidation is the expected route.
Historical Context & Evolution
Ciliary neurotrophic factor was pursued in the 1990s as a protein drug for motor-neuron disease. A 570-patient randomised trial of the recombinant protein found no benefit and dose-related harm, including more deaths at the highest dose (Miller 1996); a Cochrane review of both large trials found no survival benefit (Bongioanni 2004). A modified version was then developed for weight loss and produced modest loss over 12 weeks (Ettinger 2003). Neither programme produced an approved product. The failures were attributed less to the biology than to the molecule: a short half-life, poor passage into the brain, and systemic effects traced to receptors outside the nervous system.
The response from Khalid Iqbal’s laboratory was to shrink the molecule. Epitope mapping (testing which fragments of a protein carry its activity) identified an 11-residue active region, Peptide 6, which was neurogenic when given outside the brain (Chohan 2011). That was cut to a four-residue core and fitted with an adamantane cage, producing the compound reported as P21 in 2010 (Li 2010) and renamed P021 in all subsequent work. The patents were assigned to the Research Foundation for Mental Hygiene (US patent 9,327,011).
What followed was a decade of rodent studies from essentially one group, spanning Alzheimer models, aged rats, Down syndrome and retinal aging; autism work (Kazim 2015) and brain-injury work (Chohan 2015) used Peptide 6. No human study followed. The compound instead moved into grey-market peptide sales, where it is injected or sprayed into the nose on doses extrapolated from rodent work.
Expected Benefits
High 🟩 🟩 🟩
No benefit reaches High: P21 has never been given to a person in a published study, so no human clinical endpoint and no validated human surrogate has been measured by any research group, let alone by two independent ones.
Medium 🟩 🟩
No benefit reaches Medium: the same absence rules out both a single human trial and controlled observational data, since the entire evidence base is rodent behaviour, rodent histology (microscope examination of tissue) and cell culture.
Low 🟩
No benefit reaches Low: there are no uncontrolled human data either, as no case series, case report or registry observation of P21 use in people has been published.
Speculative 🟨
Memory and Learning in Cognitive Aging
Oral P21 reduced the age-related decline in learning and memory in 22-to-24-month-old rats and raised BDNF (Bolognin 2014). Basis is animal behaviour only; no person has been tested.
Hippocampal Neurogenesis and Synaptic Density ⚠️ Conflicted
Treated mice showed more new neurons and higher synaptic markers (Baazaoui 2017); a Bologna-led group found none in Cdkl5-knockout mice (Mottolese 2024). Evidence is animal histology. Net: the effect is unreplicated outside the inventing laboratory.
Reduction of Tau Hyperphosphorylation
Long-term oral P21 lowered abnormally phosphorylated tau in an Alzheimer mouse line (Kazim 2014) and total tau in aged-rat spinal fluid (Khatoon 2015). Mechanism is reduced GSK-3β activity. No human tau measurement exists.
Reduction of Amyloid-β Burden ⚠️ Conflicted
In Alzheimer-model mice, soluble amyloid-β fell at 15–16 months but not 21–22 months; insoluble amyloid-β was unchanged (Kazim 2014). Prenatal dosing lowered plaque load (Wei 2020). Net: the amyloid signal is inconsistent.
Survival in an Alzheimer Mouse Model
Treatment begun before overt pathology and continued for 18 months markedly reduced the mortality rate alongside reduced neurodegeneration (Baazaoui 2017). This is survival in one transgenic (genetically engineered) line, from the inventing laboratory, unreplicated.
Protection Against Retinal Aging
Chronic P21 reduced macular-degeneration-like damage (age-related loss of central vision) in the retina of aged rats and Alzheimer-model mice (Liu 2019). Basis is animal histology; no eye endpoint has been measured in people.
Benefit-Modifying Factors
-
Baseline neurotrophic state: the clearest proposed modifier. Treatment gave no memory benefit in wild-type mice (Kazim 2017) and raised no BDNF in Cdkl5-null mice (Mottolese 2024); the first report found improved learning in normal adult mice (Li 2010).
-
Genetic background: benefit was present in Alzheimer and Down syndrome models but limited in Cdkl5-null mice, where the responsible signalling appeared to be broken (Mottolese 2024). No human pharmacogenetic data exist; CNTF-receptor pathway variants are an untested candidate.
-
Sex: no difference seen in the one comparison. A Down syndrome model found no sex difference before pooling (Kazim 2017); Alzheimer-model work used female mice only (Baazaoui 2017). No human comparison exists.
-
Pre-existing health conditions: the proposed benefit is defined by the presence of neurodegenerative or neurodevelopmental pathology. Outside such a condition, the animal data provide no basis for expecting any measurable change.
-
Age and timing of initiation: in mice, dosing begun before overt pathology prevented amyloid and tau pathology (Baazaoui 2017), while treatment started after pathology was established reduced tau but left insoluble amyloid unchanged (Kazim 2014); in 22-to-24-month-old rats benefit was still seen (Bolognin 2014).
-
Baseline biomarker levels: no baseline measurement has ever been shown to predict response. Spinal-fluid tau was reduced from an elevated starting level in aged rats (Khatoon 2015), which is suggestive of a starting-level dependence, not evidence of one.
Potential Risks & Side Effects
High 🟥 🟥 🟥
No risk reaches High: P21 has never been administered to a person in a published study, so there is no human adverse-event record, clinical endpoint or validated surrogate for this compound from any research group, let alone from two.
Medium 🟥 🟥
No risk reaches Medium: the same absence rules out a single human trial and controlled observational data on P21, and the strongest human evidence in this section concerns the full-length parent protein, a different molecule.
Low 🟥
CNTF-Class Systemic Adverse Effects ⚠️ Conflicted
The full-length parent protein caused dose-related loss of appetite, weight loss, cough and more deaths at the highest dose (Miller 1996); at 0.3–2 µg/kg a variant was well tolerated, with adverse events in 78–93% of treated versus 75% of placebo participants (Ettinger 2003). Net: dose-dependent, and indirect for this fragment.
Magnitude: Nausea occurred in up to 30.3% and cough in up to 42.2% of participants given the recombinant variant versus 6.3% and 3.1% on placebo over 12 weeks, both highest at 2.0 µg/kg (Ettinger 2003); the source gives no confidence interval (CI, the range of values consistent with the data). No figure exists for P21 itself.
Injection-Site Reactions
Mild injection-site reactions were the most frequently reported adverse event when the recombinant variant of the parent protein was injected under the skin (Ettinger 2003). Evidence is indirect: a different molecule, a sterile regulated product, and supervised administration. No P21-specific rate exists.
Magnitude: Injection-site reactions occurred in 34.4–63.6% of participants given the recombinant variant versus 18.8% on placebo over 12 weeks, rising with dose (Ettinger 2003); the source gives no confidence interval, and no rate exists for P21.
Immune Response to the Peptide ⚠️ Conflicted
The parent protein raised antibodies in most patients after two weeks of injection (ACTS Study Group 1995). Evidence is indirect: a full-length protein, not this five-residue fragment. Rats given P21 showed no detectable immune reaction (Khatoon 2015). Net: documented for the parent protein only; untested for P21 in people.
Magnitude: Antibodies developed in 45–87% of participants across the recombinant-variant dose groups by the end of 12 weeks, with no dose relationship; the source reports no placebo-group antibody rate (Ettinger 2003), and no figure exists for P21.
Speculative 🟨
Substandard or Contaminated Grey-Market Product
Semaglutide vials bought from unlicensed online sellers were misbranded, impure and contaminated with bacterial toxin (Ashraf 2024). A different peptide was tested; no P21 product has been assayed. Basis is product testing, not human outcomes.
Unintended Cell Proliferation from GSK-3β Inhibition
P21’s proposed route lowers GSK-3β activity, which releases Wnt signalling (a growth-and-repair pathway whose chronic activation drives tumour growth). No tumour outcome has been measured with P21. Basis is mechanistic.
Risk-Modifying Factors
-
Route of administration: the dominant modifier. The published animal work is oral or injected into the abdominal cavity; grey-market use is injection under the skin or into the nose, which adds sterility, dosing-accuracy and local-reaction risks that no study has characterised.
-
Product provenance: risk tracks the supply chain rather than the molecule. Research-grade material carries no sterility, endotoxin (a bacterial toxin that triggers fever and inflammation) or identity guarantee for human use, and a certificate of analysis supplied by the seller is not independent verification.
-
Pre-existing health conditions: the relevant concerns are cancer history, given the GSK-3β and Wnt mechanism, and pregnancy, given that the compound was deliberately studied for effects on brain development. Neither has human data.
-
Genetic polymorphisms: no pharmacogenetic risk data exist. The compound is not known to be metabolised by cytochrome P450 enzymes, so the common variants that drive drug-interaction risk for small molecules are not the obvious candidates here.
-
Sex: unknown. The pivotal Alzheimer-model safety observations come from female mice only (Baazaoui 2017), so no sex comparison of adverse effects exists in that model, and no human comparison exists.
-
Age: older users carry the baseline risks that the parent protein’s effects would compound — appetite loss and weight loss matter more where muscle mass is already falling. This is inference from the parent compound, not a measured age interaction.
-
Baseline biomarker levels: no baseline value has been shown to predict harm. Low baseline body weight and an elevated inflammatory marker are the plausible starting points to watch, by analogy with the parent protein’s dose-related effects.
Key Interactions & Contraindications
Documented interactions:
- None identified. No human interaction or pharmacokinetic study of P21 exists, no product label exists, and no regulator has published an interaction statement, so no interaction can be placed under this label.
Theoretical interactions (inferred from mechanism, not studied in humans):
-
Lithium and other GSK-3β inhibitors (tideglusib): inferred from a shared target — both lower GSK-3β activity, so the pathway effect would be additive. Theoretical consequence is a raised tumour-promotion risk via Wnt signalling, of unknown size. No dose adjustment is definable without human data.
-
Other BDNF-raising compounds (7,8-dihydroxyflavone, 7,8-DHF prodrugs): inferred from a shared route, since both converge on TrkB signalling. Theoretical consequence is an added share of the same unquantified tumour-promotion concern. Separating administration gives no benefit, because both act over days, not hours.
-
Supplements that raise BDNF (curcumin, omega-3 fatty acids): inferred from additive effect on the same growth signal. Theoretical consequence is a small addition to the tumour-promotion concern; none has been observed, since the combination has never been given to a person.
-
Immunosuppressants and biologic agents (tocilizumab, sarilumab): inferred from a shared receptor part, gp130 (a signalling subunit used by the interleukin-6 family the parent protein belongs to), which these drugs’ target also uses. Theoretical consequence is an altered immunosuppressive effect of unknown direction.
-
Over-the-counter agents: none inferred. No over-the-counter medicine shares P21’s LIF-receptor route or its GSK-3β target at usual doses, and none has been studied with it in humans or animals.
Populations who should avoid P21:
-
Pregnant and breastfeeding women: inferred from the compound’s deliberate use to alter brain development, administered from prenatal day 8 in the mouse work (Wei 2020); a compound designed to change fetal brain development in animals has no human safety margin.
-
People with active or recent cancer: inferred from GSK-3β inhibition releasing Wnt signalling, a growth pathway implicated in tumour progression; no human data, and no source gives a threshold, stage or interval since remission for this compound.
-
Children and adolescents: inferred from the same developmental mechanism — the animal benefit is explicitly a developmental-window effect (Kazim 2017) — which means a developing brain is the most exposed, not the safest, target. No human data.
-
Anyone without an identity-verified, sterility-tested product: inferred from substandard quality documented in unlicensed online semaglutide products (Ashraf 2024); the risk here attaches to the product, not the molecule, and is not quantified for P21.
Risk Mitigation Strategies
Parameters below reflect common practice unless a citation is given; no clinical guideline, label or trial protocol for P21 exists from which to draw them.
-
Independent identity and purity assay: third-party testing of identity, purity and endotoxin on the actual vial, rather than reliance on a seller’s certificate, addresses the substandard-product risk documented in unlicensed online semaglutide vials (Ashraf 2024).
-
Lowest-exposure start with slow escalation: starting at the bottom of any reported range and holding 2–4 weeks addresses the dose-dependence of the parent protein’s harms, where adverse effects and excess deaths clustered at the highest dose (Miller 1996).
-
Body-weight and appetite tracking: weekly weighing with a stop point — commonly a 5% unintentional fall from baseline — targets the dose-related appetite and weight loss reported with the parent protein in people (Miller 1996).
-
Aseptic injection technique: single-use sterile diluent, alcohol preparation and site rotation reduce the local reaction and infection risk that follows from unsupervised subcutaneous injection of a product not manufactured for human use.
-
Avoiding overlapping mechanisms: not combining P21 with lithium, 7,8-DHF or other GSK-3β-lowering or BDNF-raising agents prevents additive activation of a pathway whose over-activation is the basis of the proliferation concern.
-
Clinician oversight with a defined stop rule: supervision by a physician holding the baseline and follow-up results addresses the core risk here — that no human toxicology exists to predict what an adverse outcome will look like.
-
Pregnancy exclusion before and during use: confirmed non-pregnancy and effective contraception address the developmental mechanism deliberately exploited in the prenatal rodent work (Wei 2020).
Therapeutic Protocol
No protocol used by leading practitioners can be described from evidence: P21 has no approved indication, no registered trial and no published human dosing study. Parameters below other than the cited animal doses reflect common practice reported by grey-market sources, not clinical evidence.
-
Standard human protocol: none exists. No dose, interval, duration or route for human use has been established in any published study, and no regulator or guideline body has evaluated one.
-
Published oral dose (rodent): 60 nmol per gram of feed, giving roughly 162 nmol per mouse per day over 18 months (Baazaoui 2017). This is the regimen behind most of the efficacy claims made for the compound.
-
Published injected dose (rodent): 750 nmol per mouse daily into the abdominal cavity for 30 days, used after the oral regimen raised no BDNF (Mottolese 2024). A 50 nmol daily brain-injury regimen used Peptide 6, not P21 (Chohan 2015).
-
Competing approach — oral: the route the animal efficacy data rest on, supported by stability in artificial gastric and intestinal fluid, as restated from the laboratory’s earlier work (Baazaoui 2017). It is not the route grey-market practice uses.
-
Competing approach — injection and intranasal: the routes used outside research, at roughly 100–500 µg daily by subcutaneous injection or 500 µg to 1 mg intranasally, which the source calls extrapolations with no approved clinical dose (Outliyr report).
-
Where sources differ: subcutaneous doses are given as 100–500 µg daily (Outliyr report) and 100–250 µg daily (Hunter Williams newsletter); intranasal 500 µg–1 mg (Outliyr report) and 1–4 mg (Hunter Williams newsletter). None rests on a human study.
-
Who popularised each approach: the oral regimen comes from the Iqbal laboratory, which holds the patents; injected and intranasal use was popularised by peptide vendors and practitioner newsletters (Hunter Williams newsletter).
-
Half-life: reported as over three hours in plasma by a review (Kazim 2016); the parent 11-residue peptide’s half-life is over six hours (Chohan 2011). Nothing is known about human half-life.
-
Single versus split dosing: unresolved. The animal work delivered the compound continuously in feed rather than as discrete doses, so the published efficacy data cannot distinguish single from split administration.
-
Best time of day: no study has compared timing. The rodent regimen was continuous through the dark and light phases, which removes any basis for a morning or evening preference.
-
Genetic polymorphisms: no pharmacogenetic data guide dose. CNTF-receptor pathway variants are a mechanistic candidate, untested; the common CYP variants that drive dosing of small molecules are not expected to apply to a peptide.
-
Sex-based differences: the one animal sex comparison, in a Down syndrome model, found no statistically significant difference in response (Kazim 2017); the Alzheimer-model work used female mice only (Baazaoui 2017). No human or dose comparison exists.
-
Age-related considerations: the only age signal is that treatment begun before overt pathology prevented it in mice (Baazaoui 2017). Nothing supports a dose adjustment for older adults, including at the upper end of the age range.
-
Baseline biomarker levels: no baseline value has been shown to predict response or set dose. Later work tied benefit to a pre-existing deficit (Mottolese 2024), against an early normal-mouse result (Li 2010); neither is a dosing rule.
-
Pre-existing conditions: response in animals depended on which pathology was present — Alzheimer and Down syndrome models responded, a Cdkl5-null model showed limited behavioural benefit and no structural change (Mottolese 2024). No human equivalent exists.
Discontinuation & Cycling
-
Intended duration: unresolved for humans. The animal work that produced the efficacy claims was continuous for 12 months (Kazim 2014) to 18 months (Baazaoui 2017), implying indefinite use rather than a course.
-
Withdrawal effects: none have been reported, and none have been looked for. The only post-stopping data come from developmental designs that tracked later outcomes, not withdrawal signs (Wei 2020), so absent reports reflect absent data, not demonstrated safety.
-
Tapering protocol: none exists. No source describes a taper, and the proposed mechanism — a shift in growth-signal expression over weeks — gives no pharmacological basis for abrupt-stop rebound.
-
Cycling for maintained efficacy: not studied. No animal or human study compared continuous with intermittent dosing, so claims that cycling preserves response have no evidence behind them either way.
-
Durability of effect after stopping: unknown. In the prenatal-dosing design, treatment stopped at three weeks of age yet differences persisted to 22 months (Wei 2020), which concerns a developmental window, not adult use.
Sourcing and Quality
-
No pharmaceutical-grade source exists: P21 has no marketing authorisation anywhere and is not on the FDA’s list of bulk substances usable in compounding (FDA 503A bulks list), so no licensed pharmacy can lawfully compound it.
-
Research-use-only supply: the identifiable commercial source is the research-chemical market, where the compound is catalogued and sold for laboratory use only, not for administration to people (MedChemExpress product page).
-
Purity benchmark from the literature: published study material was purified by reverse-phase chromatography (a laboratory separation method) to above 96% purity, its sequence confirmed by mass spectrometry (identifying a molecule by its mass) (Baazaoui 2017). Grey-market material is not held to this.
-
What to look for: an independent certificate of analysis naming the assay method, a measured purity figure rather than a claimed one, confirmed peptide identity by mass spectrometry, and an endotoxin result — none of which a seller’s own paperwork reliably provides.
-
Formulation considerations: the compound is supplied as a lyophilised (freeze-dried) powder requiring reconstitution, which places sterility, diluent choice, storage temperature and in-use stability on the user. No in-use stability data for a reconstituted human-use preparation have been published.
-
No reputable consumer brand can be named: no compounding pharmacy, supplement manufacturer or pharmaceutical supplier offers P21 for human use, so there is no quality-assured brand to identify. Vendors in this market are not subject to pharmaceutical quality oversight.
-
Identity confusion as a sourcing risk: the label “P21” also denotes the cell-cycle protein p21, which a consumer source names as the molecule it is most easily confused with (Outliyr report); ordering on the bare label alone therefore risks the wrong material.
Practical Considerations
-
Time to effect: unknown in humans. Cited animal benefits were read out after continuous dosing for 3 months in aged rats (Liu 2019), 9 to 18 months in Alzheimer-model mice (Baazaoui 2017). No short-term readout has been validated.
-
Common pitfall — the wrong molecule: P21 is easy to confuse with the cell-cycle protein p21 (CDKN1A), an unrelated tumour-suppressor protein that shares only the label; findings about that protein do not apply to this peptide (Outliyr report).
-
Common pitfall — scaling rodent doses: the published regimens are stated in nanomoles per mouse in feed, with no human pharmacokinetic bridge, so arithmetic conversion to a human dose has no validity (Baazaoui 2017).
-
Common pitfall — treating one laboratory as a body of evidence: near-identical findings across many papers from one patent-holding group constitute replication of a method, not independent confirmation; the one outside-led test of the BDNF mechanism did not reproduce it (Mottolese 2024).
-
Regulatory status: no approval exists in any jurisdiction, and the compound is absent from the FDA’s list of substances permitted in pharmacy compounding (FDA 503A bulks list). Use is therefore outside both the prescription and supplement frameworks.
-
Cost and accessibility: research suppliers quote prices on request rather than listing them (MedChemExpress product page), and a consumer source describes the cost as moderate and recurring (Outliyr report). Online availability, not evidence, explains its circulation.
Interaction with Foundational Habits
-
Sleep: direction unknown; no study has measured sleep with P21 in any species. Mechanistically an indirect bidirectional link is plausible, since BDNF expression and hippocampal neurogenesis both track sleep quality, but the compound has no reported sedating or stimulating activity and no timing consideration follows.
-
Nutrition: direct and practically relevant. The efficacy data come from the compound mixed into feed and eaten continuously, so absorption occurred with food (Baazaoui 2017). No fasted-versus-fed comparison exists, no nutrient depletion is reported, and no food to include or avoid has been identified.
-
Exercise: potentiating in mechanism, unmeasured in fact. Exercise raises BDNF through the same TrkB signalling P21 is proposed to engage, so effects would overlap rather than oppose. No study has combined them, and no timing relative to training has been examined.
-
Stress management: blunting in mechanism, unmeasured in fact. Chronic stress suppresses BDNF expression and hippocampal neurogenesis, the two processes P21 is proposed to raise, so sustained stress would work against the proposed effect. No cortisol or stress-response measurement with P21 has been published.
Monitoring Protocol & Defining Success
Before any use, a baseline set is established against which later values can be read, because no reference target exists for this compound and change from a person’s own starting point is the only interpretable signal. The sensible baseline covers body weight and appetite, a general inflammatory marker and — if the proposed mechanism is to be tracked at all — a serum growth-signal level, together with a record of current cognitive and sleep status. Ongoing measurement has no validated cadence; practice in comparable unapproved-compound settings repeats the safety set at 4 weeks, at 12 weeks, and every 6 months thereafter, with body weight checked weekly throughout. Success cannot be defined by any biomarker here: no marker has been shown to change in a person, and the only defensible reading of the panel is the absence of harm.
| Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes |
|---|---|---|---|
| Body weight | No established target; track percentage change from the individual’s own baseline | Safety check: weight loss was a dose-related effect of the parent protein; a sustained fall stops use | Same scale, fasted, same time of day; pair with a recorded appetite note. No reference range applies to an individual’s weight trajectory |
| hs-CRP | Below 1.0 mg/L, the low-risk category of the CDC/AHA statement | Safety check: the parent protein triggered an acute-phase response (a body-wide inflammatory reaction) (ACTS Study Group 1995); a rise changes use | hs-CRP: high-sensitivity C-reactive protein. Range source: Centers for Disease Control and Prevention (CDC) and American Heart Association (AHA) (Pearson 2003); a federal agency and a non-profit whose memberships derive no direct revenue from this threshold. Conventional reference range 0–3.0 mg/L. Measure only when free of acute infection, and not within 2 weeks of an illness or injury |
| Serum BDNF | No established target; track change from the individual’s own baseline | Expected to change: the proposed mechanism | Not a validated surrogate — the one outside-led animal test found no rise (Mottolese 2024). Serum and plasma values differ, and platelet release during handling dominates the result |
Qualitative markers, recorded against the same baseline:
- Appetite: the single most informative subjective marker, given that appetite loss was a dose-related effect of the parent protein in people.
- Body composition and strength: whether weight change, if any, is muscle or fat, since the parent protein’s weight effect involved muscle loss.
- Memory and word-finding: the outcome the compound is taken for; self-report is weak, but it is the only cognitive signal available outside a trial.
- Sleep quality and duration: unexamined with this compound, and a plausible route by which any cognitive change could be explained away.
- Injection-site condition: local pain, swelling or induration (a firm, hardened patch under the skin), the most frequently reported local effect in the parent protein’s trials.
Emerging Research
-
No registered trial of P21 exists: a ClinicalTrials.gov search by intervention and by free text returns no study of this compound, so no NCT ID can be given. Until one is registered, every claim about human effect remains an extrapolation from rodents.
-
Independent replication is the pivotal open question: the only outside-led in-vivo test of the BDNF mechanism corrected cell-level deficits but raised no BDNF and changed no brain structure in live mice (Mottolese 2024). A positive replication would move the benefit items up; a second failure would make the mechanism itself doubtful.
-
The nearest registered test of the strategy — completed: a 26-week phase 2a trial of LM11A-31, a small-molecule mimetic acting on the p75 neurotrophin receptor, in 242 people with mild-to-moderate Alzheimer disease (NCT03069014) completed in June 2020 with no results posted to the registry; results were published separately.
-
What that completed trial found: it met its safety endpoint and showed imaging and spinal-fluid differences favouring the drug, but no effect on cognitive tests (Shanks 2024). A biomarker-only result is the most likely shape of any future P21 trial, and it would not by itself support a cognitive claim.
-
The nearest registered test of the strategy — ongoing: the same compound is being tested against progressive supranuclear palsy (a tau disease) in a 147-participant phase 2 platform regimen with a 52-week disease-severity endpoint (NCT07264283), completing 2030. A positive result would strengthen the neurotrophin-mimetic rationale; a null result would weaken it.
-
Imaging endpoints for animal work: a Medical University of South Carolina-led group, with Iqbal as co-author, used diffusion imaging to detect brain microstructure changes with P21 in the Alzheimer mouse line (Falangola 2026), a non-invasive measure usable in people. A corrigendum corrected one page (Falangola 2026); no figure from it is relied on here.
-
The developmental-window hypothesis: the claim that neurotrophic deficiency during early brain development contributes to later disease, tested by dosing before birth (Wei 2020). If sustained it would place the compound’s value far outside adult longevity use; if not, the adult case weakens further.
-
Where the risk picture could change: no toxicology programme, carcinogenicity study or human pharmacokinetic study has been published. Any of these would be the first direct evidence on safety, and could move items currently graded Speculative in either direction.
Conclusion
P21 is a small laboratory-made peptide copied from an active fragment of a natural nerve-cell growth signal and modified so that it can reach the brain and survive digestion. In rodents it has been reported to improve learning and memory in old age, raise the birth of new nerve cells, strengthen the connections between them, reduce the two proteins that accumulate in Alzheimer brains, protect the aging retina, and lower death rates in one strain of mice bred to develop Alzheimer-like disease. Those are substantial claims, and the animal work behind them is broad, though not uniformly consistent.
What is missing is the part that matters most. No person has ever been given this compound in a published study, so nothing is known about whether any of it carries over, at what dose, or at what cost. Almost every positive finding comes from the single laboratory that invented the compound, holds its patents, and is linked to its commercial development; the one attempt by an outside group to confirm its core mechanism in living animals did not succeed. The whole protein it was derived from was tested in people and produced appetite loss, weight loss and, at high doses, more deaths.
On the present record, the case for P21 rests on animal findings with no human counterpart, and the only available supply is research-grade material of unverified identity and sterility. Nothing here is settled.